Report Code: A11446 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Periodic fever syndrome is when a child has recurrent episodes of fever. It is a group of disorders and is a genetic condition. Each episode of fever is known to last for the same amount of time. Aphthous stomatitis, periodic fever, pharyngitis, and adenitis are the most common types of periodic fever syndrome noticed in children. The diagnosis of periodic fever is based on a physical exam by a rheumatologist. A blood test, genetic test, and a review of the family medical history of the child might be essential. The major symptoms presented with periodic fever syndrome include rash, sores in the mouth, abdominal pain, and joint pain. Other symptoms may occur but they are consistent from episode to episode in a child.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the periodic fever syndrome market.
Increase in government initiatives aimed to raise public awareness regarding rare disorders such as periodic fever syndrome is aiding the industry growth
Rise in research activities and rapid technological advancements are leading to the development of new drugs, improved diagnostic facilities, and therapies, which notably contribute toward the growth of the market. New drug approvals for the treatment of periodic fever syndrome are expected to have a positive impact on the industry.
Drugs that inhibit tumor necrosis factors and interleukins in the immune system are being launched in the market; this can elicit further growth of the periodic fever market.
Other than this, in developed countries, upsurge in investments from the government in the development of advanced healthcare infrastructure will further aid in the market expansion during the forecast period.
Currently, the treatment of this syndrome is carried out with the help of oral anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs and corticosteroids, which help to control the symptoms of the disease but are unlikely to assist in the disease elimination. However, availability of limited treatment options and limited knowledge for periodic fever syndrome hamper the growth of the market, globally.
Researchers at the National Human Genome Research Institute have discovered clues to the causes of non-contagious, recurring fevers and sores that affect children. Several genes have been implicated in the periodic fever syndrome, which could lead to the development of new treatments. Owing to the nature of periodic fever syndrome, researchers have long thought that the answers may lie in genomics.
Currently, drugs that affect the immune system by inhibiting interleukins and tumor necrosis factors are gaining high traction in the market. They are often used to treat different symptoms of periodic fever syndrome. The companies that manufacture these drugs are Wyeth Ltd. (Enbrel) and AbbVie, Inc. (Humira).
However, copycat versions of tumor necrosis factor (TNF) inhibitors from Novartis, Inc. and Amgen, Inc. are now available in the EU market; this is because the patent protection for AbbVie’s Humira has come to an end in Europe.
In addition, NHS England’s Commercial Medicines Unit (CMU) is coordinating a procurement process for adalimumab with the aim of saving money.
Key Benefits of the Report
Questions Answered in the Periodic Fever Syndrome Report
Periodic Fever Syndrome Market Report Highlights
Aspects | Details |
---|---|
By Type |
|
By Treatment |
|
By Routes of Administration |
|
By End-Users |
|
By DISTRIBUTION CHANNEL |
|
By Region |
|
Key Market Players | Zydus Cadila, Takeda Pharmaceutical Co. Ltd., Horizon Therapeutics PLC, Texas Allergy Group, PLLC, Swedish Orphan Biovitrum AB, Simvastatin, Novartis AG, Regeneron Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc. |
Loading Table Of Content...
Start reading.
This Report and over 71,233+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers